TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07306624: A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination With Docetaxel in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Who Are

Sponsor: STCube, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 62 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,781,000

Rescue Site Savings

+$7,761,600

Unlock Full NCT07306624 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07306624 Rescue Dossier →